| Budget Amount *help |
¥27,300,000 (Direct Cost: ¥21,000,000、Indirect Cost: ¥6,300,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2017: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2016: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
|
|---|
| Outline of Final Research Achievements |
The final effector cells in cancer immunity are CD8 + killer T cells. However, the regulatory mechanisms by helper T cells and B cells remains unknown. In this study, we found that B-cell-deficient mice (IgA-deficient mice) exhibited higher anti-tumor immunity. We found that the proportion of Treg was decreased and that naive CD8+ T cells were pre-activated compared with wild-type CD8+ T cells. In B-cell-deficient mice, intestinal bacterial abnormalities preferentially pre-activated naive CD8 + T cells by Type-I IFN stimulation, which were circulating between gut and periphery. We elucidated a complex ant-itumor immune mechanism that is comprehensively regulated by Treg, B cells and intestinal environmental factors.
|
